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Background: The emphasis placed on the activities of mobile teams in the detection of gambiense human African
trypanosomiasis (HAT) can at times obscure the major role played by fixed health facilities in HAT control and
surveillance. The lack of consistent and detailed data on the coverage of passive case-finding and treatment further
constrains our ability to appreciate the full contribution of the health system to the control of HAT.
Methods: A survey was made of all fixed health facilities that are active in the control and surveillance of gambiense
HAT. Information on their diagnostic and treatment capabilities was collected, reviewed and harmonized. Health
facilities were geo-referenced. Time-cost distance analysis was conducted to estimate physical accessibility and the
potential coverage of the population at-risk of gambiense HAT.
Results: Information provided by the National Sleeping Sickness Control Programmes revealed the existence of 632
fixed health facilities that are active in the control and surveillance of gambiense HAT in endemic countries having
reported cases or having conducted active screening activities during the period 2000-2012. Different types of
diagnosis (clinical, serological, parasitological and disease staging) are available from 622 facilities. Treatment with
pentamidine for first-stage disease is provided by 495 health facilities, while for second-stage disease various types of
treatment are available in 206 health facilities only. Over 80% of the population at-risk for gambiense HAT lives within
5-hour travel of a fixed health facility offering diagnosis and treatment for the disease.
Conclusions: Fixed health facilities have played a crucial role in the diagnosis, treatment and coverage of
at-risk-population for gambiense HAT. As the number of reported cases continues to dwindle, their role will
become increasingly important for the prospects of disease elimination. Future updates of the database here
presented will regularly provide evidence to inform and monitor a rational deployment of control and surveillance
efforts. Support to the development and, if successful, the implementation of new control tools (e.g. new diagnostics
and new drugs) is crucial, both for strengthening and expanding the existing network of fixed health facilities by
improving access to diagnosis and treatment and for securing a sustainable control and surveillance of gambiense HAT.Introduction
Alongside the continued, albeit geographically limited, en-
gagement of bilateral cooperation and Non-Governmental
Organizations (NGOs), it was the commitment of private
sector in 2001 to support WHO that marked a turning
point in the fight against human African trypanosomiasis
(HAT) [1]. From that moment, control actions by the* Correspondence: simarrop@who.int
1World Health Organization, Control of Neglected Tropical Diseases,
Innovative and Intensified Disease Management, Geneva, Switzerland
Full list of author information is available at the end of the article
© 2014 World Health Organization/Food and ANational Sleeping Sickness Control Programmes (NSSCPs)
improved across the continent, and a dramatic decrease in
the number of gambiense HAT cases followed. The annual
number of cases reported to WHO by disease-endemic
countries dropped by 73% from 25,865 in 2000 to 7,106 in
2012 [2].
This observed drop in cases reported was accompan-
ied and made possible by strengthened capacity of
NSSCPs to perform active and passive case-detection, as
well as an improvement in reporting [3]. The withdrawal
of NGOs which focused on HAT emergencies (while ingriculture Organization of the United Nations.
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December 2012 only two were registered) and the diffi-
culties in recruiting patients for clinical trials to develop
new tools for HAT control, support the notion that the
trend reported over the last decade reflects a real abate-
ment of disease transmission in the field. Furthermore,
substantially improved management and reporting of
data – embodied in the HAT Atlas initiative [4,5] – also
contribute to the reliability of the available epidemio-
logical information.
Nevertheless, because of the occurrence of gambiense
HAT in remote rural areas and the weakness of health
systems, an unspecified number of sleeping sickness
cases still escape detection and reporting. For gambiense
HAT little is known of the true extent of this underre-
porting phenomenon, and specific studies are needed to
estimate its magnitude and thereby accurately to assess
the progress made in curbing transmission globally. At
the same time, some insights into the likelihood of
underdetection/underreporting can be gained by looking
at the distribution and intensity of control and surveil-
lance activities involving both mobile teams and fixed
health facilities.
Arguably, a narrow focus on active case-finding activ-
ities alone may give the impression that only a small
proportion of the population at-risk of HAT is reached
by control and surveillance activities. In fact, while re-
cent estimates put the population at risk of gambiense
HAT at approximately 57 million people [6,7], only an
average of 2 million are screened every year by mobile
teams (period 2000-2012) (data not shown). Active sur-
veillance alone appears inadequate to ensure a satisfac-
tory coverage of populations at-risk of gambiense HAT,
and consequently it may seem reasonable to question
the reported abatement in disease transmission. How-
ever, the role played by fixed health facilities embedded
in the health system must be taken into account if a
complete picture of the coverage and outcomes of HAT
control and surveillance is to be drawn.
Indeed, control of gambiense HAT has relied, in addition
to the impressive and well known active case-finding sur-
veys carried out by mobile teams, also on the quiet contri-
bution of passive screening performed in fixed health
structures. For example, in the period 2000-2012, 93,561
cases of gambiense HAT (48.9% of the reported total) were
diagnosed by passive case-finding carried out in fixed
health facilities (Table 1).
However, the lack of consistent and detailed data on
the extent, capacities and coverage of passive case-
finding and treatment constrains our ability to appreci-
ate its full relevance in HAT control and surveillance.
The present study aims to contribute to filling this gap.
The paper explores the geographic distribution and
the diagnostic and treatment capabilities of fixed healthfacilities involved in gambiense HAT control and surveil-
lance. It also aims to estimate the at-risk population po-
tentially covered by passive case-finding and treatment
by using Geographic Information Systems (GIS).
The inventory of this passive surveillance and treatment
network provides the dimension of what is available today.
At the same time, it gives insights into the work needed
in terms of capacity development and improvement and
expansion of the network, aiming at covering the whole
population at risk.
The paper focuses on all endemic countries having
reported gambiense HAT cases or having conducted
active screening activities during the period 2000-2012 (i.e.
Angola, Benin, Burkina Faso, Cameroon, Central African
Republic, Chad, Congo, Côte d’Ivoire, Democratic Republic
of the Congo, Equatorial Guinea, Gabon, Ghana, Guinea,
Mali, Nigeria, Sierra Leone, South Sudan, Togo and
Uganda). Capabilities for diagnosis and treatment in non-
endemic countries have been reviewed elsewhere [8].
Rhodesiense HAT being characterized by different epi-
demiological patterns and approaches to disease control
is not directly considered in this study.
Methods
Data collection
Fixed health facilities active in gambiense HAT control
and surveillance were identified through direct inter-
views with the coordinators of the NSSCPs. Standard-
ized forms were circulated requesting information on
the name and location of the health structures, and on
their diagnostic and treatment capabilities for HAT. The
survey started in December 2012 and was completed in
August 2013.
Diagnostic capabilities were categorized as follows.
Clinical diagnosis (DxC) refers to the ability of health
centres systematically to raise a clinical suspicion of try-
panosomal infection and refer the suspect to the next
level for further diagnosis or, if available, to perform it in
the same facility. Serological diagnosis (DxS) concerns
the capability of performing serological tests, thus iden-
tifying serological suspects. In this context, the sero-
logical test considered is the card agglutination test for
trypanosomiasis – CATT [9]. Parasitological diagnosis
(DxP) pertains to the competence of the health centre to
execute any type of parasitological test in order to confirm
trypanosome infection in clinical or serological suspects
through direct observation of the parasite in body fluids.
Health centres were also classified according to their cap-
ability to carry out the stage determination (DxPh) by
examination of cerebrospinal fluid obtained through lum-
bar puncture.
Treatment capabilities were categorized in a similar
fashion. This includes treatment of first stage infections
with pentamidine (Tx1P), and treatment of second-stage
Table 1 Cases of gambiense HAT diagnosed by active and passive case-finding (period: 2000-2012)
Country Active cases Passive cases Total
No [%] No [%] No
Angola 10,856 47.6 11,962 52.4 22,818
Benin 0 N.a. 0 N.a. 0
Burkina Faso 0 N.a. 0 N.a. 0
Cameroon 191 85.7 32 14.3 223
Central African Republic 5,095 60.0 3,396 40.0 8,491
Chad 1,984 53.8 1,701 46.2 3,685
Congo 3,276 66.3 1,667 33.7 4,943
Côte d’Ivoire 214 32.8 438 67.2 652
Democratic Republic of the Congo 69,971 54.6 58,199 45.4 128,170
Equatorial Guinea 126 68.5 58 31.5 184
Gabon 167 44.4 209 55.6 376
Gambia – – – – –
Ghana 0 0.0 1 100.0 1
Guinea 525 49.7 531 50.3 1,056
Guinea-Bissau – – – – –
Liberia – – – – –
Mali 0 N.a. 0 N.a. 0
Niger – – – – –
Nigeria 11 8.7 115 91.3 126
Senegal – – – – –
Sierra Leone 0 N.a. 0 N.a. 0
South Sudan 4,140 25.0 12,399 75.0 16,539
Togo 0 N.a. 0 N.a. 0
Uganda 1,087 27.6 2,853 72.4 3,940
TOTAL 97,643 51.1 93,561 48.9 191,204
“-”, no data reported.
“N.a.” not applicable.
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nifurtimox-eflornithine combination therapy – NECT
(Tx2N).
All data on the HAT health centres provided by NSSCPs
were harmonized and assembled in a database. Mapping
was subsequently carried out using geo-referencing proce-
dures already described [10].
Data analysis
Physical accessibility to HAT diagnosis and treatment
was estimated through a cost-distance function. This
type of geographical functions determines the shortest
weighted distance (or least cumulated travel time-cost)
from any location to the nearest destination. In our
study, travel cost was measured in time units, and the
destinations were represented by health facilities having
capabilities for HAT diagnosis and treatment.
The time-cost of travel was derived from a recently
generated ‘friction’ layer for Africa [11]. In this type ofgeo-spatial dataset, such GIS maps as land cover, water
bodies, slope and road network are combined to empir-
ically derived travel speeds to estimate a pixel-by-pixel
travel time. Various means of transportation are contem-
plated, depending on the network infrastructure and ter-
rain. The friction grid utilized in this study has a spatial
resolution of approximately 1-km (i.e. 30 arcseconds).
Importantly, affordability (or economic cost of travel) is
not considered in this model.
The least time-cost path function enabled a map of acces-
sibility to be generated across the study countries, whereby
the shortest travel time to the closest HAT diagnostic or
treatment facility was estimated for each pixel. This enabled
population coverage to be assessed for different cumulated
travel times. In particular, results are provided for three dif-
ferent travel time-cost thresholds: 1, 3 and 5 hours.
Total population coverage was subsequently stratified
by level of gambiense HAT risk. To this end, a previously
derived risk surface for gambiense HAT was used, which
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and human population layers [7]. From this dataset three
broad categories of risk were extracted: high and very high
(≥ 1 HATcase per 103 people per annum – p.a.), moderate
(≥ 1 HAT case per 104 people and < 1 HAT case per 103
people p.a.), and low and very low (≥ 1 HAT case per 106
people and < 1 HATcase per 104 people p.a.) (Figure 1).
For estimating both the total population coverage and
the coverage of at-risk population, the dataset Landscan™
2009 was used [12]. This was the same layer previously
used to estimate at-risk population [7], and therefore it
provided a precise baseline for comparison. Uncertain-
ties and limitations of the available global human popu-
lation layers, including Landscan™, have been discussed
in a number of papers (e.g. [13,14]).
Ethical considerations
The study is based on the analysis of a database obtained
through administrative data provided by health authorities
in the selected countries. No experimental research was
carried on humans nor on animals. The database does not
contain any individual or attributable information. There-
fore for this study no Institutional Review Board was
sought and the Helsinki declaration and Ethical Guidelines
for Biomedical Research were not applicable.Figure 1 The risk of T. b. gambiense infection in Africa. Adapted from [
period 2000-2009 and on Landscan™ human population layers for the same p
of tsetse flies is provided. The palpalis group (Genus: Glossina, subgenus: NemResults
Fixed health facilities for diagnosis and treatment of
gambiense human African trypanosomiasis
Information provided by the NSSCPs revealed the exist-
ence of 632 fixed health facilities that are involved in the
control and surveillance of gambiense HAT in disease-
endemic countries.
Their diagnostic and treatment capacities are summa-
rized in Table 2, while the complete list of health facil-
ities including the names and geographical coordinates
is provided in Additional file 1.
Diagnosis is available in 622 facilities, 84.2% of which
are found in the Democratic Republic of the Congo
(DRC). Although all of the 622 centres are able to iden-
tify clinical suspects, only 56% of them are able to go
further performing serological test. The number of cen-
tres able to carry out parasitological diagnosis (DxP) and
disease staging (DxPh) decreases to 49% and 39% re-
spectively, mainly due to the need for complex tools and
highly skilled staff.
Access to treatment for gambiense HAT is slightly
more limited (495 health centres – 81.6% of which in
DRC). While all of these centres are able to offer treat-
ment for first-stage disease, only 36.4% can offer first
line treatment for second-stage disease (Tx2N). This is7]. Risk is based on the reported number of gambiense HAT cases in the
eriod [6]. As a backdrop, the predicted distribution of the palpalis group
orhina) includes all the major vector species of gambiense HAT.
Table 2 Number of fixed health facilities providing diagnosis and treatment for gambiense HAT
Diagnosis Treatment Total
DxC DxS DxP DxPh Total Dx Tx1P Tx2M Tx2E Tx2N Total Tx2 Total Tx
Angola* 19 19 18 17 19 17 12 13 0 13 17 19
Benin 3 3 0 0 3 0 0 0 0 0 0 3
Burkina Faso 2 2 2 1 2 1 1 1 0 1 1 2
Cameroon 8 0 7 7 8 9 6 5 5 6 9 9
Central African Republic 11 9 9 9 11 10 8 7 7 8 10 11
Chad 4 4 4 4 4 10 4 4 4 4 10 10
Congo 10 10 8 7 10 9 5 3 3 5 9 10
Côte d’Ivoire 4 4 1 1 4 4 1 1 1 1 4 4
Democratic Republic of the Congo 524 273 229 173 524 404 147 144 144 147 404 524
Equatorial Guinea 5 1 4 1 5 4 1 1 1 1 4 5
Gabon 1 1 1 1 1 4 2 2 2 2 4 4
Ghana 1 0 0 0 1 1 0 0 0 0 1 1
Guinea 3 2 2 2 3 2 1 1 1 1 2 3
Mali 6 1 1 1 6 1 1 1 1 1 1 6
Nigeria 5 5 5 5 5 5 5 0 0 5 5 5
Sierra Leone 0 0 0 0 0 0 0 0 0 0 0 0
South Sudan 10 6 7 7 10 10 7 7 7 7 10 10
Togo 2 2 0 0 2 0 0 0 0 0 0 2
Uganda 4 4 4 4 4 4 4 4 4 4 4 4
Total 622 346 302 240 622 495 205 194 180 206 495 632
Study area: disease-endemic countries having reporting cases or having conducted active screening activities during the period 2000-2012. DxC: clinical diagnosis;
DxS: serological diagnosis; DxP: parasitological diagnosis; DxPh: disease staging. Tx1P: treatment of first-stage infection with pentamidine; Tx2M: treatment of
second-stage infection with melarsoprol; Tx2E: treatment of second-stage infection with eflornithine; Tx2N: treatment of second-stage infection with
nifurtimox-eflornithine combination therapy (NECT); Tx2: treatment of second stage.
*After closing the study, information was received that Angola upgraded the Tx2E centres to Tx2N.
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Figure 2 shows the geographic distribution of the health
structures involved in gambiense HAT diagnosis (A) and
treatment (B). In this figure, no distinction is made be-
tween different levels of diagnostic or treatment capabil-
ities. Separate maps showing the distribution of centres
able to perform the various types of diagnosis and treat-
ment are provided in Additional file 2. Distribution maps
at the national and focus level will be made available from
the WHO HAT web site (http://www.who.int/trypanoso-
miasis_african/en/).
Diagnosis coverage by fixed health facilities of population
at-risk of gambiense human African trypanosomiasis
The map of physical accessibility to HAT diagnostic fa-
cilities is shown in Figure 3. In the study countries, we
estimate that 31, 85 and 154 million people are respect-
ively within 1, 3 and 5 hours travel of a facility with cap-
acity for HAT diagnosis.
Focusing on gambiense HAT at-risk population, their
coverage by diagnostic facilities is summarized in Table 3.
Our analysis indicates that 23.4, 40.2, and 47.4 millionpeople at risk are respectively within 1, 3 and 5 hours
travel of a facility with capacity for gambiense HAT diag-
nosis. This corresponds to 41, 71, and 83% of the total at-
risk population. For the 10-hour travel threshold, the
coverage of at-risk population is 96% (Additional file 3).
Coverage is not homogeneous across the risk categor-
ies, with higher risk categories being characterized by
comparatively better coverage. For example, for popula-
tions at high and very high risk, coverage is estimated at
48, 77 and 87% for the travel time thresholds of 1, 3 and
5 hours respectively. These percentages decrease for
moderate and for low and very low risk categories – the
health systems deploying better equipped facilities and
skilled staff in areas where transmission of the disease is
more intense.
Full details for a range of travel-times, for all study
countries and for all risk categories are provided in Add-
itional file 3. These country-level data indicate that there
are no major differences between countries in terms of
the proportion of at-risk population potentially covered
by HAT diagnostic facilities.
Cost-distance analysis was also conducted separately for
the different types of diagnosis. Results are summarized in
Figure 2 Geographic distribution of fixed health facilities having capacities for gambiense HAT diagnosis (A) and treatment (B). Data
were collected by WHO between December 2012 and August 2013 from National Sleeping Sickness Control Programmes in the study countries
(i.e. Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Equatorial
Guinea, Gabon, Ghana, Guinea, Mali, Nigeria, Sierra Leone, South Sudan, Togo and Uganda).
Simarro et al. International Journal of Health Geographics 2014, 13:4 Page 6 of 11
http://www.ij-healthgeographics.com/content/13/1/4
Figure 3 Travel time (or physical accessibility) to health facilities having capabilities for diagnosis of gambiense HAT [hours]. Physical
accessibility was calculated through a cost-distance function. Travel cost was measured in time units, and the destinations were represented by
health facilities having capabilities for HAT diagnosis (Figure 2A). The time-cost of travel was derived from a ‘friction’ layer for Africa [11].
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all study countries and for all risk categories are provided
in Additional file 4.
Treatment coverage by fixed health facilities of
population at-risk of gambiense human African
trypanosomiasis
The map of physical accessibility to HAT treatment fa-
cilities is shown in Additional file 5. We estimate that in
the study countries 27, 73 and 133 million people are re-
spectively within 1, 3 and 5 hours travel of a facility with
capacity for gambiense HAT treatment.
Looking at population at risk, the coverage by treatment
facilities is summarized in Table 5, while full details for a
range of travel-times, for all study countries and for all risk
categories are provided in Additional file 6. Our analysis
indicates that 21.6, 38.8, and 46.5 million people at risk
are respectively within 1, 3 and 5 hours travel of a facilityTable 3 People at risk of gambiense HAT that are potentially
Risk category People at risk People at risk potentia
≤ 1-hour travel









Total 56,983 23,387 41
People at risk are stratified by risk categories as defined in [7].with capacity for gambiense HAT treatment. This corre-
sponds to 38, 68, and 82% of the total population at risk.
For the 10-hour travel threshold, the coverage of at-risk
population is 95% (Additional file 6).
Cost-distance analysis was also conducted separately
for the different types of treatment. Results are sum-
marized in Table 6, while detailed data for a range of
travel-times, for all study countries and for all risk cat-
egories are provided in Additional file 7. All facilities
involved in gambiense HAT treatment have capacity for
treatment of the first-stage of the disease. Lower cover-
age is available for the treatment of the second-stage of
the disease.
Conclusions
The decreasing trend in the reported number of gam-
biense HAT cases has led to target the disease for elim-
ination in the WHO Road Map on Neglected Tropicalcovered by facilities with diagnostic capabilities
lly covered by facilities with HAT-diagnostic capabilities
≤ 3-hour travel ≤ 5-hour travel
(No. persons × 103) % of at risk
population
(No. persons × 103) % of at risk
population
3,963 77 4,516 87
10,382 72 12,156 84
25,861 69 30,780 82
40,207 71 47,452 83
Table 4 People at risk of gambiense HAT that are potentially covered by facilities with different types of diagnostic
capabilities for HAT
Type of diagnosis At-risk population potentially covered [%]
≤ 1 hour travel time ≤ 3 hour travel time ≤ 5 hour travel time
VH-H M L-VL VH-H M L-VL VH-H M L-VL
DxC 48 41 40 77 72 69 87 84 82
DxS 41 38 37 73 70 65 86 83 79
DxP 41 37 37 73 69 64 85 82 78
DxPh 41 35 35 72 68 63 85 81 78
DxC: clinical diagnosis; DxS: serological diagnosis; DxP: parasitological diagnosis; DxPh: disease staging. VH: Very high risk; H: High risk; M: Moderate risk; L: Low
risk; VL: Very low risk. People at risk are stratified by risk categories as defined in [7].
Simarro et al. International Journal of Health Geographics 2014, 13:4 Page 8 of 11
http://www.ij-healthgeographics.com/content/13/1/4Disease [15]. However, the low number of people at risk
covered by active case-finding surveys is often cited to
raise doubts on the reliability of the reported figures. In
this study we show that a narrow focus on the intensity
of active case-finding is inadequate to fully describe the
coverage of HAT control and surveillance activities.
Gambiense HAT is a chronic disease that is character-
ized by a sufficiently long duration [16] to allow passive
case detection in fixed health facilities to complement
the coverage of active case detection. At the same time,
the interval between infection and diagnosis in fixed
health structure allowed the persistence and the spread
of the disease. As a matter of fact, active screening by
mobile teams that has been decisive in tackling the wor-
risome situation of HAT at the beginning of this century,
can only be conducted in selected villages of determined
areas of disease transmission. Covered locations are
rarely visited more than once a year, and the interval be-
tween successive visits is often longer. Even on the occa-
sion when a village is visited by a mobile team, coverage
is unfortunately far from 100% [17]. Because of these
limitations of active case-finding, the role of the fixed
health facilities in gambiense HAT transmission areas
has been extremely important to fill a part of the screen-
ing and coverage gap. Indeed, passive screening detected
93,561 cases during the period 2000-2012, which repre-
sent approximately half of the total cases reported.Table 5 People at risk of gambiense HAT that are potentially
Risk category People at risk People at risk potentia
≤ 1-hour travel









Total 56,983 21,586 38
People at risk are stratified by risk categories as defined in [7].The present analysis reveals the existence of a network
of fixed health facilities involved in the passive control
and surveillance of gambiense HAT. A census of the
diagnosis and treatment capabilities was made for the
632 fixed health facilities identified. It must be stressed
that our survey did not address the quality control of
services provided in the fixed health facilities involved in
HAT control and surveillance, nor did it explore popula-
tion attendance. The results illustrate the substantial at-
tempts made by the health system in disease-endemic
countries in tackling the disease, although efforts on
capacity building and equipment must be undertaken to
get this network fully operational. Over 80% of the
population at-risk lives within 5-hour travel of a fixed
health facility offering diagnosis and treatment for gam-
biense HAT. The results also indicate that coverage for
clinical diagnosis is the most widely available, while ac-
cess to serological and parasitological diagnosis becomes
progressively more difficult. This observation supports
the notion that that the current test for serological
screening (CATT), although very useful for serological
mass screening by mobile teams, does not fulfil the re-
quirements for its use in the rural health facilities where
gambiense HAT is endemic – most notably because of
the format (50 tests per vial) and the need for cold chain
and electric power. The new Individual Screening Tests
(IST, often called rapid diagnostic tests) do not requirecovered by facilities with treatment capabilities for HAT
lly covered by facilities with HAT-treatment capabilities
≤ 3-hour travel ≤ 5-hour travel
(No. persons × 103) % of at risk
population
(No. persons × 103) % of at risk
population
3,947 76 4,506 87
10,211 71 11,995 83
24,620 66 29,924 80
38,777 68 46,424 82
Table 6 People at risk of gambiense HAT that are potentially covered by facilities with different types of treatment
capabilities for HAT
Type of treatment At-risk population potentially covered [%]
≤ 1 hour travel time ≤ 3 hour travel time ≤ 5 hour travel time
VH-H M L-VL VH-H M L-VL VH-H M L-VL
Tx1P 47 39 36 76 71 66 87 83 80
Tx2M 38 34 27 70 66 62 84 81 76
Tx2E 38 33 32 70 66 59 84 80 72
Tx2N 31 30 26 62 63 52 74 77 64
Tx1P: treatment of first-stage infection with pentamidine; Tx2M: treatment of second-stage infection with melarsoprol; Tx2E: treatment of second-stage infection
with eflornithine; Tx2N: treatment of second-stage infection with nifurtimox-eflornithine combination therapy (NECT). VH: Very high risk; H: High risk; M: Moderate
risk; L: Low risk; VL: Very low risk. People at risk are stratified by risk categories as defined in [7].
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tial to expand the network of fixed health facilities able
to detect serological suspects – which is presently avail-
able only in 55.6% of the facilities able to detect clinical
suspects – and therefore they could widen and improve
access to gambiense HAT diagnosis [18]. Concerning
parasitological diagnosis, the coverage gap can partly be
ascribed to the cumbersome nature of and the skilled
staff required by the current parasitological diagnostic
tests. First evaluation on clinical samples of new molecular
techniques procedures (i.e. the loop-mediated isothermal
amplification — LAMP) has shown similar performance
to conventional PCR [19]. However, LAMP is still more
complicated than the parasitological methods available
and requires further studies to assess its accuracy. There-
fore it does not fulfil all requirements to replace the la-
borious process for demonstrating the presence of the
parasite in body fluids of people giving positive results in
serological screening tests. At this point in time, the weak-
ness of laboratory capacities in the rural health facilities
remains a challenge for parasitological diagnosis of gam-
biense HAT [20].
Concerning treatment, thanks to the fact that some
cases diagnosed and staged in highest centres as first
stage can be referred for treatment to lower health cen-
tres, 82% of the people at risk of gambiense HAT have
access to a centre offering treatment for first-stage pa-
tients within a 5-hour travel-time, while 69% have access
to a health care facility administering the recommended
first line treatment for second-stage gambiense HAT
(NECT) within the same travel-time threshold. These
figures show that people affected by second-stage gam-
biense HAT have to make more efforts to receive appro-
priate treatment. This is mainly because of the complexity
of administration and the demanding logistics of current
first line treatment for second-stage gambiense HAT. The
hopes to overcome these hurdles rest in the ongoing
development of new drugs not requiring skilled staff
and complex equipment (i.e. fexinidazole and oxaborol)
[21,22]. An oral, safe drug, effective for both stages of the
disease could greatly improve access to treatment; at thesame time, it would remove the need for staging through
lumbar puncture, which is not always well accepted and
can only be offered by 38.5% of the facilities involved in
the treatment of gambiense HAT.
In the light of the new challenges to achieve sustain-
able elimination of gambiense HAT, the meeting on
HAT elimination held in Geneva in December 2012 [23]
emphasized the importance of maintaining mobile teams
in selected areas and in particular epidemiological cir-
cumstances, as well as the value of reinforcing the health
system and involving it fully in passive control and sur-
veillance. This message has been voiced by the disease-
endemic countries [23] and in a recent WHO Expert
Committee on HAT [2]. Strengthening and expanding
fixed health facilities involved in control and surveillance
to reach 100% of people at risk require the provision of
appropriate tools and capacity building. Support from
both international partners and from operational na-
tional teams is needed to monitor and evaluate the net-
work, as well as to collect and analyze data obtained and
to provide appropriate response.
It is important to note that two factors have contrib-
uted to the good performance of passive detection in re-
cent years: the knowledge of the disease among health
staff and among affected communities. This knowledge
facilitates diagnosis both at the level of fixed health facil-
ities, but also at the community level, where infected in-
dividuals can be identified and advised to visit a hospital
for proper diagnosis and care. Retirement of skilled staff
and the decreasing number of cases in the community
reduce familiarity with the disease and can greatly de-
crease the effectiveness of passive diagnosis. A need exists
therefore for capacity building of health staff, for less
complicated control tools, and for awareness-raising cam-
paigns among populations at risk of gambiense HAT.
Moreover, low attendance rates in some health care
facilities (the average annual attendance rate of health
services in DRC is estimated at 0.15 per inhabitant [24])
are unfortunately not only due to difficulties at the tech-
nical level (i.e. skilled staff and adapted tools) but are also
at the structural level. Indeed, attendance of populations
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sibility, but also on economic and socio-cultural factors
and on the perceived benefit of skilled care [25]. Further-
more, due to the location of the main fixed health struc-
ture (towns), passive screening is likely to address more
urban than rural people. Therefore, attention must be paid
to appreciate the level of attendance of population at risk
of HAT (e.g. number of people screen by new IST by year
and by village of origin), as well as their characteristics
(sex, age, urban/rural, activities, etc.) in order to evaluate
the coverage of fixed health facilities in the case of HAT
surveillance.
On the other hand, attendance to facilities providing
services of diagnosis of HAT does not mean that the
tests available are applied automatically. Several visits
are sometimes necessary before HAT diagnostic tools
are applied, and awareness of staff in the presence of the
disease is required to prescribe their use [26]. Continu-
ous monitoring and evaluation are therefore needed,
with a view to ensuring that an effective surveillance of
gambiense HAT is in place to sustain the disease elimin-
ation process.
The data and coverage estimates herewith presented
will be regularly updated, thus continuously providing
evidence to inform a rational deployment of control and
surveillance efforts. Coverage estimates of population at
risk will also provide indicators to monitor the process
of elimination of gambiense HAT [23].Additional files
Additional file 1: Fixed health facilities that are active in the control
and surveillance of gambiense HAT. Table S1. Fixed health facilities
that are active in the control and surveillance of gambiense HAT in
Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad,
Congo, Côte d’Ivoire, Equatorial Guinea, Gabon, Ghana, Guinea, Mali,
Nigeria, Sierra Leone, South Sudan, Togo and Uganda. Table S2. Fixed
health facilities that are active in the control and surveillance of
gambiense HAT in the Democratic Republic of the Congo.
Additional file 2: Geographic distribution of fixed health facilities
having capacities for diagnosis of gambiense human African
trypanosomiasis. Figure S1. Geographic distribution of fixed health
facilities having capacities for clinical diagnosis of gambiense HAT (A) and
serological diagnosis (B). Figure 2. Geographic distribution of fixed
health facilities having capacities for parasitological diagnosis of
gambiense HAT (A) and stage determination (B). Figure 3. Geographic
distribution of fixed health facilities having capacities for treatment of
gambiense HAT first-stage infections with pentamidine (A) and second-
stage infection with melarsoprol (B). Figure 4. Geographic distribution of
fixed health facilities having capacities for treatment of gambiense HAT
second-stage infections with eflornithine (A) and with nifurtimox-
eflornithine combination therapy (B).
Additional file 3: Diagnosis coverage by fixed health facilities of
population at-risk of gambiense human African trypanosomiasis.
Diagnosis coverage is provided for a range of travel-times, for all study
countries and for all HAT-risk categories.
Additional file 4: Coverage for the different types of diagnosis.
Annex_DxC.xlsx: Clinical diagnosis coverage is provided for a range of
travel-times, for all study countries and for all HAT-risk categories.Annex_DxS.xlsx: Serological diagnosis coverage is provided for a range of
travel-times, for all study countries and for all HAT-risk categories.
Annex_DxP.xlsx: Parasitological diagnosis coverage is provided for a range
of travel-times, for all study countries and for all HAT-risk categories.
Annex_DxPh.xlsx: Disease staging coverage is provided for a range of
travel-times, for all study countries and for all HAT-risk categories.
Additional file 5: Travel time (or physical accessibility) to health
facilities having capabilities for treatment of gambiense HAT
[hours]. Physical accessibility was calculated through a cost-distance
function. Travel cost was measured in time units, and the destinations
were represented by health facilities having capabilities for HAT treat-
ment. The time-cost of travel was derived from a ‘friction’ layer for Africa
[11].
Additional file 6: Treatment coverage by fixed health facilities of
population at-risk of gambiense human African trypanosomiasis.
Treatment coverage is provided for a range of travel-times, for all study
countries and for all HAT-risk categories.
Additional file 7: Coverage for the different types of treatment.
Annex_Tx1P.xlsx: Coverage for treatment of first-stage infection with
pentamidine is provided for a range of travel-times, for all study countries
and for all HAT-risk categories. Annex_Tx2M.xlsx: Coverage for treatment
of second-stage infection with melarsoprol is provided for a range of
travel-times, for all study countries and for all HAT-risk categories.
Annex_Tx2E.xlsx: Coverage for treatment of second-stage infection with
eflornithine is provided for a range of travel-times, for all study countries
and for all HAT-risk categories. Annex_Tx2N.xlsx: Coverage for treatment
of second-stage infection with nifurtimox-eflornithine combination therapy
is provided for a range of travel-times, for all study countries and for all
HAT-risk categories.Competing interests
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